AGN—It’s curious that investors are reading the tea leaves so bullishly with respect to the Botox sBLA for migraine while simultaneously ignoring the competitive threat from Xeomin, which just got FDA approval for its first indication (#msg-52866968) and has a robust phase-3 program for cosmetic indications that is nearing completion.
News 
Market Data 
Discover 
AI
